Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) CEO Seth Lederman bought 5,300 shares of the company’s stock in a transaction that occurred on Tuesday, December 26th. The shares were bought at an average price of $3.61 per share, with a total value of $19,133.00. Following the transaction, the chief executive officer now owns 11,166 shares of the company’s stock, valued at approximately $40,309.26. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.
Tonix Pharmaceuticals Holding Corp. (NASDAQ TNXP) traded up $0.02 during mid-day trading on Thursday, reaching $3.54. 67,400 shares of the company’s stock traded hands, compared to its average volume of 329,574. Tonix Pharmaceuticals Holding Corp. has a fifty-two week low of $2.85 and a fifty-two week high of $9.40. The company has a market capitalization of $27.46, a price-to-earnings ratio of -1.05 and a beta of 2.62.
An institutional investor recently bought a new position in Tonix Pharmaceuticals stock. B. Riley Financial Inc. acquired a new stake in shares of Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 378,138 shares of the company’s stock, valued at approximately $1,637,000. B. Riley Financial Inc. owned about 5.05% of Tonix Pharmaceuticals as of its most recent SEC filing. 17.57% of the stock is owned by institutional investors and hedge funds.
Tonix Pharmaceuticals Company Profile
Tonix Pharmaceuticals Holding Corp., a clinical-stage pharmaceutical company, engages in developing pharmaceutical products for central nervous system disorders. The companys lead program focuses on post-traumatic stress disorder (PTSD) that is characterized by chronic disability, inadequate treatment options, high utilization of healthcare services, and economic burden.
What are top analysts saying about Tonix Pharmaceuticals? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Tonix Pharmaceuticals and related companies.